Third quarter 2020 results

Sanofi Q3 2020 business EPS growth of 8.8% at CER

Third quarter 2020 results were reviewed by management during a conference call with the financial community.

We achieved strong growth in our treatment for type 2 inflammation disorders and vaccines during Q3. We helped transform the lives of thousands of patients and reduced the spread of vaccine-preventable diseases, even as we continue to fight COVID-19.
Paul Hudson
Chief Executive Officer
Q1-2020 Investor Results

Q3 2020 infographic

Paul Hudson comments on Q3 2020 results

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies